DEA reiterates «final authority» on cannabis reclassification

In a letter recently addressed to Congress, the Drug Enforcement Administration (DEA) reaffirms its «final authority» over any decision to reclassify cannabis, regardless of the recommendations of the Department of Health and Human Services (HHS).

As stakeholders eagerly await the outcome, the complex interplay between federal agencies, lawmakers, and the public is evident.

To Reclassify or Not to Reclassify Cannabis

In 2022, the Biden administration launched a review of federal cannabis policies. Last year, the U.S. Department of Health and Human Services (HHS) officially recommended that cannabis be reclassified from Schedule I to Schedule III of the Schedule of Controlled Substances. The Schedules classify substances based on their level of danger, with Schedule I being the most restrictive; it recognizes no medical use and is associated with a high potential for abuse.

Once the HHS has issued its recommendation «Last August, »the DEA is conducting its own review,'" states the letter, which was sent last month.

«The DEA has the final authority to classify, reclassify, or declassify a drug under the Controlled Substances Act, after reviewing the relevant statutory and regulatory criteria and the scientific and medical assessment provided by the Department of Health and Human Services (HHS),» the document states.

This clarification frustrated lawmakers, including Senator Earl Blumenauer, who co-chairs the Congressional Cannabis Caucus. He and 30 other bipartisan lawmakers are urging the DEA to consider the «merits» of cannabis legalization during its review.

The DEA’s response, however, provides little insight into these concerns, sticking to a procedural approach and failing to address the key arguments presented by lawmakers.

Lack of Transparency at the HHS

The HHS recommendation to reclassify cannabis from Schedule I to Schedule III, based on a scientific assessment, set in motion the current review process. However, the details of this recommendation remain shrouded in secrecy, as hundreds of pages of explanatory notes sent to the DEA are available only in a heavily redacted form.

This lack of transparency prevents stakeholders from fully understanding the reasoning behind the HHS recommendation, which further complicates the decision-making process.

While a coalition of six U.S. governors called on the Biden administration to reclassify cannabis Before the end of last year, 29 former U.S. attorneys spoke out against such a measure, calling on the administration to keep cannabis in Schedule I. Six former DEA directors and five former White House drug policy coordinators also expressed their opposition to the HHS recommendation.

The outcome of the DEA exam will have far-reaching implications for the cannabis policy reform in the United States. Advocates and lawmakers continue to call for a comprehensive approach, urging the DEA to go beyond Schedule III and consider complete decriminalization—that is, removing cannabis from the list of controlled substances and decriminalizing it at the federal level.

Changes in public opinion, as reflected in a Gallup poll in which seven out of ten Americans support a change in cannabis policy, adding weight to the argument in favor of a more progressive stance on cannabis regulation in the United States.